DHR Announces Ownership of Over 99% of Vision Shares and Close of Offer Period
Washington, D.C., January 4, 2007 -- Danaher Corporation (NYSE: DHR) announced today that its tender offer to acquire all of the shares of Vision Systems Limited (ASX: VSL) closed as of 7:00pm (Melbourne time) on January 4, 2007. As of the close of the offer period, Danaher had acquired over 99% of the outstanding Vision shares. Danaher intends to acquire the remainder of the Vision shares by means of a compulsory acquisition process available under Australian law.
Founded in 1987 and headquartered in Melbourne, Australia, Vision has operations in Australia, the United States and the United Kingdom. Vision is a manufacturer and marketer of automated instruments including the Peloris(TM) rapid tissue processor and the Bond(TM)-maX advanced staining system, as well as Novocastra(TM) antibodies and biochemical reagents for biopsy-based detection of cancer and infectious diseases.
Danaher Corporation is a leading manufacturer of Professional Instrumentation, Industrial Technologies, and Tools and Components (http://www.danaher.com).
Statements in this release that are not strictly historical may be “forward-looking” statements. These forward-looking statements include statements about Danaher’s acquisition of shares in connection with the compulsory acquisition process and any other statements about future expectations, beliefs, goals, plans or prospects. There are a number of important risks and uncertainties that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements. These risks and uncertainties include, among other things, the risks and uncertainties set forth in Danaher’s filings with the United States Securities and Exchange Commission. These forward-looking statements speak only as of the date of this release and Danaher does not intend to update any forward-looking statement.
Please contact:
Matt R. McGrew
Vice President, Investor Relations
Danaher Corporation
2099 Pennsylvania Avenue
Washington, D.C. 20006
Telephone: (202) 828-0850
Fax: (202) 828-0860
